Patents by Inventor Bjorn Walse

Bjorn Walse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDES FOR TREATMENT OF DIABETES
    Publication number: 20210009648
    Abstract: The present disclosure concerns agents and their use in the treatment of endocrine, nutritional and/or metabolic diseases in a mammal. The disclosure furthermore concerns novel peptides.
    Type: Application
    Filed: September 16, 2020
    Publication date: January 14, 2021
    Inventors: Jan Alenfall, Pontus Dunér, Anna Hultgårdh Nilsson, Björn Walse
  • Peptides for treatment of diabetes
    Patent number: 10815283
    Abstract: The present disclosure concerns agents and their use in the treatment of endocrine, nutritional and/or metabolic diseases in a mammal. The disclosure furthermore concerns novel peptides.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: October 27, 2020
    Assignee: Follicum AB
    Inventors: Jan Alenfall, Pontus Dunér, Anna Hultgårdh Nilsson, Björn Walse
  • PEPTIDES FOR TREATMENT OF DIABETES
    Publication number: 20200095297
    Abstract: The present disclosure concerns agents and their use in the treatment of endocrine, nutritional and/or metabolic diseases in a mammal. The disclosure furthermore concerns novel peptides.
    Type: Application
    Filed: October 29, 2019
    Publication date: March 26, 2020
    Inventors: Jan Alenfall, Pontus Dunér, Anna Hultgårdh Nilsson, Björn Walse
  • Synthetic peptides and their use
    Patent number: 9132165
    Abstract: The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumors.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: September 15, 2015
    Assignee: Pergamum AB
    Inventors: Margit Mahlapuu, Camilla Björn, Veronika Sjöstrand, Björn Walse, Bo Svenson
  • Human lactoferrin derived peptides and their use
    Patent number: 8846608
    Abstract: The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumors.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: September 30, 2014
    Assignee: Pergamum AB
    Inventors: Margit Mahlapuu, Camilla Björn, Veronika Sjöstrand, Björn Walse, Bo Svenson
  • NEW SYNTHETIC PEPTIDES AND THEIR USE
    Publication number: 20140031296
    Abstract: The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumours.
    Type: Application
    Filed: January 25, 2012
    Publication date: January 30, 2014
    Applicant: PERGAMUM AB
    Inventors: Margit Mahlapuu, Camilla Björn, Veronika Sjöstrand, Björn Walse, Bo Svenson
  • Antimicrobial peptides and use thereof
    Patent number: 8076286
    Abstract: The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: December 13, 2011
    Assignee: Dermagen AB
    Inventors: Artur Schmidtchen, Martin Malmsten, Björn Walse
  • CONJUGATES BETWEEN A VARIANT STAPHYLOCOCCAL ENTEROTOXIN E SUPERANTIGEN AND A TARGETING ANTIBODY THAT BINDS TO A CANCER-ASSOCIATED CELL SURFACE STRUCTURE
    Publication number: 20100111978
    Abstract: The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.
    Type: Application
    Filed: September 28, 2009
    Publication date: May 6, 2010
    Applicant: ACTIVE BIOTECH AB
    Inventors: GORAN FORSBERG, EVA ERLANDSSON, PER ANTONSSON, BJORN WALSE
  • NOVEL ANTIMICROBIAL PEPTIDES AND USE THEREOF
    Publication number: 20090312265
    Abstract: The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
    Type: Application
    Filed: February 12, 2007
    Publication date: December 17, 2009
    Applicant: Dermagen AB
    Inventors: Artur Schmidtchen, Martin Malmsten, Björn Walse
  • Methods for treating a subject having cancer by the administration of a conjugate between a variant staphylococcal entertoxin E superantigen and an antibody that binds to the 5T4 antigen
    Patent number: 7615225
    Abstract: The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: November 10, 2009
    Assignee: Active Biotech AB
    Inventors: Goran Forsberg, Eva Erlandsson, Per Antonsson, Bjorn Walse
  • NOVEL ANTIMICROBIAL PEPTIDES AND USE THEREOF
    Publication number: 20090143299
    Abstract: The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
    Type: Application
    Filed: February 10, 2007
    Publication date: June 4, 2009
    Inventors: Artur Schmidtchen, Martin Malmsten, Bjorn Walse
  • Novel Antimicrobial Peptides
    Publication number: 20080069849
    Abstract: The invention relates to the use of peptides, wherein at least one amino acid residue has been substituted to improve the efficacy of the antimicrobial peptide for the manufacturing of an antimicrobial composition. The composition can be used as a pharmaceutical composition to combat microorganisms, such as bacteria, virus, fungus, parasites as well as yeast.
    Type: Application
    Filed: November 17, 2005
    Publication date: March 20, 2008
    Applicant: Dermagen AB
    Inventors: Artur Schmidtchen, Martin Malmsten, Bjorn Walse
  • Novel engineered superantigen for human therapy
    Publication number: 20070082001
    Abstract: The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.
    Type: Application
    Filed: November 21, 2006
    Publication date: April 12, 2007
    Applicant: ACTIVE BIOTECH AB
    Inventors: Goran Forsberg, Eva Erlandsson, Per Antonsson, Bjorn Walse
  • Engineered superantigen for human therapy
    Patent number: 7125554
    Abstract: The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: October 24, 2006
    Assignee: Active Biotech AB
    Inventors: Goran Forsberg, Eva Erlandsson, Per Antonsson, Bjorn Walse
  • Novel engineered superantigen for human therapy
    Publication number: 20030039655
    Abstract: The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.
    Type: Application
    Filed: July 6, 2001
    Publication date: February 27, 2003
    Inventors: Goran Forsberg, Eva Erlandsson, Per Antonsson, Bjorn Walse